Kamran Qureshi, MD
Gastroenterology · Lake St Louis, MONPI 1417119926
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $236,373 of the $279,253 with a category attached, or 84.6%. 20 manufacturers reported payments, led by Gilead at 32.9% of the total. 2025 is the largest year on record at $101,639, more than ten times the $260 reported in 2019. Among gastroenterology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 240 payments — averaging $1163.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$92K
- Madrigal Pharmaceuticals$88K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$68K
- Intercept Pharmaceuticals, Inc.$13K
- Phathom Pharmaceuticals, Inc.$13K
- Albireo Pharma, Inc.$3K
- plus $2K from 14 others
Across 17 payments — averaging $5961.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$98K
- Ipsen Pharma SAS$4K
What the payments were for
- Consulting fees$12,6605%
- Speaking & faculty fees$236,37385%
- Travel & lodging$21,4788%
- Food & beverage$8,6783%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 80 | $91,997 |
| Madrigal Pharmaceuticals | 65 | $88,217 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 43 | $68,191 |
| Intercept Pharmaceuticals, Inc. | 16 | $13,475 |
| Phathom Pharmaceuticals, Inc. | 11 | $12,759 |
| Albireo Pharma, Inc. | 2 | $2,949 |
| Mallinckrodt Hospital Products Inc. | 4 | $333 |
| Ipsen Biopharmaceuticals, Inc | 3 | $313 |
| Novo Nordisk | 3 | $168 |
| Alnylam Pharmaceuticals Inc. | 1 | $164 |
| E.r. Squibb & Sons, L.L.C. | 1 | $121 |
| Mirum Pharmaceuticals, Inc. | 1 | $121 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $118 |
| AstraZeneca | 1 | $93 |
| Dova Pharmaceuticals | 2 | $66 |
| Echosens North America, Inc. | 1 | $58 |
| Dynavax Technologies Corporation | 2 | $41 |
| AbbVie | 1 | $31 |
| Conmed Corporation | 1 | $21 |
| Genentech USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$279,253 in reported general payments places this provider in the 95th percentile of 374 gastroenterology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 116 | $424,055 |
| VemlidyTenofovir Alafenamide | 34 | $52,708 |
| Envarsus XrTacrolimus | 14 | $17,876 |
| EliquisApixaban | 16 | $14,894 |
| Ursodiol | 78 | $13,096 |
| Everolimus | 13 | $8,964 |
| Tacrolimus | 66 | $8,074 |
| Mycophenolate Mofetil | 25 | $3,416 |
| Lactulose | 38 | $2,318 |
| Azathioprine | 27 | $1,285 |
| Tenofovir Disoproxil Fumarate | 23 | $1,036 |
| Pantoprazole Sodium | 56 | $935 |
| Mycophenolic AcidMycophenolate Sodium | 15 | $728 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 36 | $679 |
| Omeprazole | 38 | $572 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $68,191 | $424,055116 claims |
| GileadVemlidy | $91,997 | $52,70834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 374 gastroenterology providers in Missouri.
Other gastroenterology in Lake St Louis
- Gregory SayukSaint Louis$1.1M
- Katie SchroederSaint Louis$730K
- David AlpersSaint Louis$616K
- Laith Al MomaniKansas City$249K
- Ahmed SaeedKansas City$246K
- Parakkal DeepakSaint Louis$205K
- Bradley AndersonColumbia$194K
- Mauricio Lisker MelmanSaint Louis$179K
- Matthew CiorbaSaint Louis$156K
- Bruce BaconSaint Louis$138K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.